Ptc Therapeutics (PTCT) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $15.9 million.
- Ptc Therapeutics' Net Income towards Common Stockholders rose 11490.43% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $751.7 million, marking a year-over-year increase of 26586.97%. This contributed to the annual value of -$363.3 million for FY2024, which is 4202.16% up from last year.
- Latest data reveals that Ptc Therapeutics reported Net Income towards Common Stockholders of $15.9 million as of Q3 2025, which was up 11490.43% from -$64.8 million recorded in Q2 2025.
- In the past 5 years, Ptc Therapeutics' Net Income towards Common Stockholders ranged from a high of $866.6 million in Q1 2025 and a low of -$198.9 million during Q2 2023
- Its 5-year average for Net Income towards Common Stockholders is -$66.1 million, with a median of -$126.7 million in 2022.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 9173.51% in 2021, then skyrocketed by 104627.63% in 2025.
- Over the past 5 years, Ptc Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$143.3 million in 2021, then decreased by 19.28% to -$170.9 million in 2022, then grew by 8.83% to -$155.8 million in 2023, then soared by 57.71% to -$65.9 million in 2024, then surged by 124.13% to $15.9 million in 2025.
- Its Net Income towards Common Stockholders was $15.9 million in Q3 2025, compared to -$64.8 million in Q2 2025 and $866.6 million in Q1 2025.